Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kymera Therapeutics, Inc.

28.57
-5.0100-14.92%
Post-market: 29.120.5500+1.93%16:38 EDT
Volume:1.35M
Turnover:40.95M
Market Cap:1.86B
PE:-9.58
High:33.52
Open:33.14
Low:28.34
Close:33.58
Loading ...

Kymera Therapeutics Reports Q3 2024 Earnings and Strategic Shift

TIPRANKS
·
01 Nov 2024

Kymera Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary

Reuters
·
01 Nov 2024

U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners -- WSJ

Dow Jones
·
01 Nov 2024

Stock Track | Kymera Therapeutics Plunges on Q3 Revenue Miss and Strategic Pivot

Stock Track
·
01 Nov 2024

Kymera Therapeutics: Strategic Focus and Promising Trials Justify Buy Rating

TIPRANKS
·
01 Nov 2024

Truist Trims Price Target on Kymera Therapeutics to $53 From $54, Keeps Buy Rating

MT Newswires Live
·
01 Nov 2024

Kymera Therapeutics Inc : Piper Sandler Cuts Target Price to $56 From $60

THOMSON REUTERS
·
31 Oct 2024

Kymera Therapeutics Shares Fall After Q3 Loss, Lower Revenue

MT Newswires Live
·
31 Oct 2024

Stock Track | Kymera Therapeutics Plunges After Q3 Revenue Miss and Strategic Pivot

Stock Track
·
31 Oct 2024

Stock Track | Kymera Therapeutics Plunges 5.6% Pre-Market Following Q3 Results, Strategic Shift

Stock Track
·
31 Oct 2024

Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates

Zacks
·
31 Oct 2024

Kymera Therapeutics Inc Files for Mixed Shelf Offering; Size Not Disclosed - SEC Filing

THOMSON REUTERS
·
31 Oct 2024

BRIEF-Kymera Therapeutics Announces Third Quarter 2024 Financial Results

Reuters
·
31 Oct 2024

Kymera Therapeutics Q3 2024 GAAP EPS $(0.82) Beats $(0.84) Estimate, Sales $3.740M Miss $10.360M Estimate

Benzinga
·
31 Oct 2024

Kymera Therapeutics Inc: KT-295, New Tyk2 Degrader, Selected as Development Candidate to Advance Into Phase 1 Clinical Trial in H1 2025

THOMSON REUTERS
·
31 Oct 2024

Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update

THOMSON REUTERS
·
31 Oct 2024

Kymera Therapeutics: to Only Advance KT-333 (Stat3) and KT-253 (Mdm2) Beyond Phase 1 With a Partner

THOMSON REUTERS
·
31 Oct 2024

Kymera Therapeutics Inc: to Shift Focus and Resources From Oncology to Its Expanding Immunology Pipeline

THOMSON REUTERS
·
31 Oct 2024

Kymera Therapeutics Q3 Operating Expenses USD 75.865 Million

THOMSON REUTERS
·
31 Oct 2024

Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update

GlobeNewswire
·
31 Oct 2024